GURUFOCUS.COM » STOCK LIST » Financial Services » Asset Management » Biotech Growth Trust (The) PLC (LSE:BIOG) » Definitions » Financial Strength

Biotech Growth Trust (The) (LSE:BIOG) Financial Strength : 7 (As of Sep. 2023)


View and export this data going back to 1997. Start your Free Trial

What is Biotech Growth Trust (The) Financial Strength?

Biotech Growth Trust (The) has the Financial Strength Rank of 7.

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.

GuruFocus does not calculate Biotech Growth Trust (The)'s interest coverage with the available data. Biotech Growth Trust (The)'s debt to revenue ratio for the quarter that ended in Sep. 2023 was -0.45. Altman Z-Score does not apply to banks and insurance companies.


Biotech Growth Trust (The) Financial Strength Calculation

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

Biotech Growth Trust (The)'s Interest Expense for the months ended in Sep. 2023 was £-0.52 Mil. Its Operating Income for the months ended in Sep. 2023 was £0.00 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was £11.44 Mil.

Biotech Growth Trust (The)'s Interest Coverage for the quarter that ended in Sep. 2023 is

The higher the ratio, the stronger the company's financial strength is.

2. Debt to revenue ratio. The lower, the better.

Biotech Growth Trust (The)'s Debt to Revenue Ratio for the quarter that ended in Sep. 2023 is

Debt to Revenue Ratio=Total Debt (Q: Sep. 2023 ) / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0 + 11.437) / -25.7
=-0.45

3. Altman Z-Score.

Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

The zones of discrimination were as such:

When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.

Altman Z-Score does not apply to banks and insurance companies.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biotech Growth Trust (The)  (LSE:BIOG) Financial Strength Explanation

The maximum rank is 10. Companies with rank 7 or higher will be unlikely to fall into distressed situations. Companies with rank of 3 or less are likely in financial distress.

Biotech Growth Trust (The) has the Financial Strength Rank of 7.


Biotech Growth Trust (The) Financial Strength Related Terms

Thank you for viewing the detailed overview of Biotech Growth Trust (The)'s Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.


Biotech Growth Trust (The) (LSE:BIOG) Business Description

Traded in Other Exchanges
Address
25 Southampton Buildings, London, GBR, WC2A 1AL
Biotech Growth Trust (The) PLC is a United Kingdom-based investment trust. Its business objective is to provide its investors with capital appreciation by investing in the biotechnology industry around the world. The company portfolio comprises emerging biotechnology companies across North America, Europe, and Asia, of which North America accounts for the investment share.